PARP Inhibition and Ovarian Cancer - prIME Oncology
prIME Decision Points
prIME Decision Points

PARP Inhibition and Ovarian Cancer

From Supporting Act to Center Stage in Patient Care

Not a member of My prIME? Join now for instant access.

Hear from the experts about the best strategies to optimize patient outcomes in ovarian cancer including PARP inhibition, the continuum-of-care approach, and systemic therapy. A clinical scenario that includes patient history, laboratory results, and options for next steps in treatment provides the opportunity for expert commentary and insight for decision making in the care of your patients with ovarian cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Dec 3, 2018

Expiration Date

Dec 3, 2019

  • Philipp Harter, MD, PhDKliniken Essen-Mitte
    Essen, Germany
  • Susana Banerjee, MBBS, MA, PhD, FRCPRoyal Marsden Hospital
    Institute of Cancer Research
    London, United Kingdom
  • Clinical case with advanced ovarian cancer from diagnosis through initial systemic treatment to the management of recurrent disease
  • BRCA testing and DNA repair defects
  • PARP inhibitors
  • Combination strategies

This educational activity is designed for medical oncologists, gynecologists, and other healthcare providers involved in the management of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Identify patients with platinum-sensitive ovarian cancer who are appropriate candidates for PARP inhibition treatment
  • Describe implementation of data from clinical trials investigating PARP inhibition in pretreated ovarian cancer into patient care

This educational activity is supported by a grant from AstraZeneca.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of IME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality IME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Banerjee has disclosed receipt of fees for membership on advisory boards and for lectures from AstraZeneca, Clovis, Gamamabs, Merck, PharmaMar, Seattle Genetics, Roche, and Tesaro. She also has received educational grants from AstraZeneca and Janssen Cilag. She also disclosed support for clinical trials/contracted research from Amgen, Astex, AstraZeneca, Aprea, Array, Astellas, Bristol-Myers Squibb, Clovis, Endocyte, Enita, Glycotope, Genentech, GlaxoSmithKline, Immunogen, Lilly, MedImmune, Merck, Merck Sharp & Dohme, Millennium, Nucana, Pfizer, PharmaMar, Roche, Takeda, and Tesaro. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Harter has disclosed that he holds board membership with AstraZeneca, Immunogen, Lilly, Roche, Stryker, and Tesaro. He also disclosed speaking and teaching for AstraZeneca, Roche, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – chair of Inbiomotion Scientific and Clinical Advisory Board; consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.